A Phase I Study of GRN163L in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
GRN163L is a telomerase template antagonist with in vitro and in vivo activity in a variety
of tumor model systems. Telomerase is an enzyme that is active primarily in tumor cells and
is crucial for the indefinite growth of tumor cells. Inhibition of telomerase may result in
antineoplastic effects.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label
Maximum tolerated dose
First 3 weeks
Yes
Stephen Kelsey, MD
Study Director
Geron Corporation
United States: Food and Drug Administration
GRN163L CP14A011
NCT00718601
July 2008
October 2011
Name | Location |
---|---|
Fred Hutchinson Cancer Research Center | Seattle, Washington 98109 |
St. Vincent's Comprehensive Cancer Center | New York, New York 10011 |
Karmanos Cancer Center | Detroit, Michigan 48201 |